Cytokines in cancer immunity and immunotherapy

Authors

  • Mark J. Smyth,

    Corresponding author
    1. Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center (Peter Mac), Victoria, Australia.
      * Mark J. Smyth
      Cancer Immunology Program
      Trescowthick Laboratories
      Peter MacCallum Cancer Center (Peter Mac)
      Locked Bag 1, A'Beckett Street 8006
      Victoria, Australia
      Tel.: +61 3 9656 3728
      Fax: +61 3 9656 1411
      E-mail: m.smyth@pmci.unimelb.edu.au
    Search for more papers by this author
  • Erika Cretney,

    1. Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center (Peter Mac), Victoria, Australia.
    Search for more papers by this author
  • Michael H. Kershaw,

    1. Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center (Peter Mac), Victoria, Australia.
    Search for more papers by this author
  • Yoshihiro Hayakawa

    1. Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center (Peter Mac), Victoria, Australia.
    Search for more papers by this author

* Mark J. Smyth
Cancer Immunology Program
Trescowthick Laboratories
Peter MacCallum Cancer Center (Peter Mac)
Locked Bag 1, A'Beckett Street 8006
Victoria, Australia
Tel.: +61 3 9656 3728
Fax: +61 3 9656 1411
E-mail: m.smyth@pmci.unimelb.edu.au

Abstract

Summary:  The concept that the immune system recognizes and controls cancer was first postulated over a century ago, and cancer immunity has continued to be vigorously debated and experimentally tested. Mounting evidence in humans and mice supports the involvement of cytokines in tumor initiation, growth, and metastasis. The idea that the immune system detects stressed, transformed, and frankly malignant cells underpins much of the excitement currently surrounding new cytokine therapies in cancer treatment. In this review, we define the contrasting roles that cytokines play in promoting tumor immunity, inflammation, and carcinogenesis. We also discuss the more promising aspects of clinical cytokine use in cancer patients.

Ancillary